TG101348, also known as Fedratinib or SAR302503, is a small molecule inhibitor that acts against Janus kinase 2 (JAK2), used primarily in the pharmaceutical industry for cancer treatment. It is a pyrazole derivative with the chemical name N-(4-(4-(cyclopentylamino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)phenyl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)acetamide. Its molecular formula is C27H36N8O2, and its molecular weight is 524.63 g/mol. Its CAS No is 936091-26-8.
According to Google trends, some of the top ten keywords associated with TG101348 include:
Some synonyms of TG101348 include fedratinib, SAR-302503, TG-101348, and 936091-26-8.
Health Benefits of TG101348
TG101348 is still in the early stages of research, and its benefits are still being studied. However, TG101348 has been found to be a potent inhibitor of JAK2, and as such, it may have potential in the treatment of myelofibrosis, a blood cancer characterized by the abnormal growth of cells in bone marrow.
Potential Effects of TG101348
TG101348 has been found to inhibit the growth of cells in bone marrow and reduce fibrosis, resulting in improvement in anemia, thrombocytopenia, and symptoms related to spleen enlargement, in patients with myelofibrosis. The JAK2-targeted therapy works by blocking a specific gene that drives the disease. The treatment has also shown promise in treating lymphoma, leukemia, and other types of cancer.
Product Mechanism of TG101348
TG101348 targets JAK2 and is a small molecule inhibitor of the JAK-STAT signaling pathway. JAK-STAT signaling helps control cell division, survival, and differentiation of hematopoietic stem cells in the bone marrow. When the genes that regulate JAK2 signaling are mutated, it becomes overactive, leading to the development and progression of cancer. TG101348 blocks the activation of this gene and stops the growth of malignant cells.
Safety of TG101348
The safety of TG101348 is still being studied to determine the appropriate dosage and risks associated with the treatment. More information on effects on pregnancy, fetus and nursing babies needs to be confirmed with scientific research.
Side Effects of TG101348
The side effects of TG101348 are still being studied, and more research is needed to determine the safety of the product in humans. Some potential side effects of the product include anemia, thrombocytopenia, nausea, vomiting, and fatigue.
Dosing Information of TG101348
The recommended dose of TG101348 is 400 mg taken orally once daily. The treatment is oral and usually taken with food. Treatment should be stopped in case of severe side effects such as anaphylaxis, heart failure, or hepatitis.
Conclusion
TG101348 is a valuable product used in cancer treatment for inhibiting growth of malignant cell by blocking the gene that drives the disease. However, it is still largely in the early stages of research, and more research is needed to determine the safety and efficacy of TG101348. TG101348 offers potential benefits for patients with blood cancer such as myelofibrosis and polycythemia vera, as well as lymphoma and leukemia. As with any new treatment or product, patients should consult with a qualified health professional before use. The research progress on TG101348 will further establish its place as a valuable clinical treatment tool for various diseases such as cancer in the industry.
